Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924410 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16421257 | 0.78 | PDPK1 (0.55) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8253156 | 0.78 | PDPK1 (0.55) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2581504 | 0.76 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2402634 | 0.76 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2578485 | 0.76 | PDPK1 (0.53) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13223489 | 0.73 | PDPK1 (0.50) | PDPK1SLC6A2SLC6A4SLC6A3 | |
| Tametraline SCHEMBL11694846 | 0.73 | — | — | |
| Tametraline SCHEMBL1237910 | 0.73 | — | — | |
| Tametraline SCHEMBL4619211 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
| WO-2007013673-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | PDPK1 1125/4885SLC6A2 4656/4885SLC6A4 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.